In Segment C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. - "Our study discovered the vital job on the KLF16/MYC regulatory https://abbv-744therapeuticpotent57902.creacionblog.com/31902216/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline